HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials

Antiviral Research

Volumn 130, Issue , 2016, Pages 118-129

  Ludmerer, Steven W ^a   Hirano, Tomona ^b   Black, Stuart ^a   Howe, Anita Y M ^a   Chang, Wei ^c   Takase, Akiko ^b   Nakamura, Keisuke ^b   Tanaka, Yoshiyuki ^b   Kumada, Hiromitsu ^d   Hayashi, Norio ^e   Nickle, David ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Merck Sharp Dohm Res Labs Japan   (Japan)

^c WUXI APPTEC   (China)

^d TORANOMON HOSPITAL   (Japan)

^e KANSAI ROSAI HOSPITAL   (Japan)

Author keywords

HCV; Resistance; Vaniprevir

Indexed keywords

MONTIRELIN; PROTEINASE INHIBITOR; VANIPREVIR; ANTIVIRUS AGENT; INDOLE DERIVATIVE; MK-7009;

ANTIVIRAL RESISTANCE; ARTICLE; DRUG TREATMENT FAILURE; FOLLOW UP; GENETIC POLYMORPHISM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; METHODOLOGY; MOLECULAR CLONING; NONHUMAN; PHASE 3 CLINICAL TRIAL; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TREATMENT OUTCOME; VIRAL GENETICS; VIROLOGY; VIRUS MUTATION; AMINO ACID SUBSTITUTION; CLASSIFICATION; CLINICAL TRIAL; CODON; COMBINATION DRUG THERAPY; DNA SEQUENCE; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; MOLECULAR EVOLUTION; MUTATION; TREATMENT FAILURE;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CODON; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; EVOLUTION, MOLECULAR; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INDOLES; MUTATION; PHYLOGENY; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84963805752     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.03.004     Document Type: Article

References (35)

1. N. Akuta, F. Suzuki, T. Fukushima, Y. Kawamura, H. Sezaki, Y. Suzuki, T. Hosaka, M. Kobayashi, T. Hara, M. Kobayashi, S. Saitoh, Y. Arase, K. Ikeda, and H. Kumada Prediction of treatment efficacy and telaprevir -resistant variants after triple therapy in patients infected with Hepatitis C virus genotype 1 J. Clin. Micro 51 2013 2862 2868
2. N. Akuta, F. Suzuki, Y. Seko, Y. Kawamura, H. Sezaki, Y. Suzuki, T. Hosaka, Mas Kobayashi, T. Hara, Mar Kobayashi, S. Saitoh, Y. Arase, K. Ikeda, and H. Kumada Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1 J. Med. Virol. 85 2013 1028 1036
3. N. Akuta, F. Suzuki, H. Sezaki, Y. Suzuki, T. Hosaka, Mas Kobayashi, Mar Kobayashi, S. Saitoh, K. Ikeda, and H. Kumada Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b J. Med. Virol. 86 2014 1314 1322
4. Y. Asahina, K. Tsuchiya, N. Tamaki, I. Hirayama, T. Tanaka, M. Sato, Y. Yasui, T. Hosokawa, K. Ueda, T. Kuzuya, H. Nakanishi, J. Itakura, Y. Takahashi, M. Kurosaki, N. Enomoto, and N. Izumi Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection Hepatology 52 2010 518 527
5. H. Chung, T. Ueda, and M. Kudo Changing trends in hepatitis C infection over the past 50 years in Japan Intervirology 53 2010 39 43
6. J. Dutheil, T. Pupko, A. Jean-Marie, and N. Galtier A model-based approach for detecting coevolving positions in a molecule Mol. Biol. Evol. 22 2005 1919 1928
7. R.C. Edgar Muscle: a multiple sequence alighnment method with reduced time and space complexity BMC Bioinforma. 5 2004 113
8. Editors of the Drafting Committee for Hepatitis Management Guidelines: The Japan Society of Hepatology Guidelines for the management of hepatitis C virus infection: first edition, May 2012, the Japan Society of Hepatology Hepatol. Res. 43 2013 1 34
9. J. Felsenstein Phylogenies and the comparative method Am. Nat. 125 1985 15
10. P.B. Gilbert, V. Novitsky, and M. Essex Covariability of selected amino acid positions for hiv type 1 subtypes C and B AIDs Res. Hum. Retroviruses 21 2005 1016 1030
11. S. Guindon, J.F. Dufayard, V. Lefort, M. Anisimova, W. Hordijk, and O. Gascuel New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of phyml 3.0 Syst. Biol. 59 2010 307 321
12. N. Hayashi, N. Izumi, H. Kumada, T. Okanoue, H. Tsubouchi, H. Yatsuhashi, M. Kato, R. Ki, Y. Komada, C. Seto, and S. Goto Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial J. Hepatol. 61 2014 219 227
13. N. Hayashi, M. Nakamuta, T. Takehara, H. Kumada, A. Takase, A.Y. Howe, S.W. Ludmerer, and N. Mobashery Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naïve Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study J. Gastroenterol. 51 2016 390 403
14. Y. He, M.S. King, D.J. Kempf, L. Lu, H.B. Lim, P. Krishnan, W. Kati, T. Middleton, and A. Molla Relative replication capacity and selective advantage profiles of protease inhibitor-resistant Hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system Antimicrob. Agents. Chemother. 52 2008 1101 1110
15. N. Izumi, N. Hayashi, H. Kumada, T. Okanoue, H. Tsubouchi, H. Yatsuhashi, M. Kato, R. Ki, Y. Komada, C. Seto, and S. Goto Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies J. Gastroenterol. 49 2014 941 953
16. H. Kumada, N. Hayashi, N. Izumi, T. Odanoue, H. Tsubouchi, H. Yatsuhashi, M. Kato, K. Rito, Y. Komada, C. Seto, and S. Goto Simeprevir (TMC435) once daily with peginterferon-2b and ribavirin in patients with genotype 1 hepatitis C infection: the CONCERTO-4 study Hepatol. Res. 45 2015 501 513
17. H. Kumada, S. Mochida, F. Suzuki, K. Chayama, Y. Karino, K. Nakamura, G. Fujimoto, A.Y. Howe, S.W. Ludmerer, and N. Mobashery Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: phase III studies J. Gastroenterol. Hepatol. 2016 10.1111/jgh.13328 [Epub ahead of print]
18. H. Kumada, Y. Suzuki, K. Ikeda, J. Toyota, Y. Karino, K. Chayama, Y. Kawakami, A. Ido, K. Yamamoto, K. Takaguchi, N. Izumi, K. Koike, T. Takehara, N. Kawada, M. Sata, H. Miyagoshi, T. Eley, F. McPhee, A. Damokosh, H. Ishikawa, and E. Hughes Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection Hepatology 59 2014 2083 2091
19. H. Kumada, J. Toyota, T. Okanoue, K. Chayama, H. Tsubouchi, and N. Hayashi Telaprevir with peginterferon and ribavirin for treatment-naïve patients chronically infected with HCV of genotype 1 in Japan J. Hepatol. 56 2012 78 84
20. N.J. Liverton, S.S. Carroll, J. DiMuzio, C. Fandozzi, D.J. Graham, D. Hauzda, M.K. Holloway, S.W. Ludmerer, J.A. McCauley, C.J. McIntyre, D.B. Olsen, M.T. Rudd, M. Stahlhut, and J.P. Vacca Mk-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease Antimicrob. Agents Chemother. 54 2010 305 311
21. N.J. Liverton, M.K. Holloway, J.A. McCauley, M.T. Rudd, J.W. Butcher, S.S. Carroll, J. DiMuzio, C. Fandozzi, K.F. Gilbert, S.-S. Mao, C.J. McIntyre, K.T. Nguyen, J.J. Romano, M. Stahlhut, B.-L. Wan, D.B. Olsen, and J.P. Vacca Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease J. Am. Chem. Soc. 130 2008 4607 4609
22. E. Lontok, P. Harrington, A. Howe, T. Kieffer, J. Lennerstrand, O. Lenz, F. McPhee, H. Mo, N. Parkin, T. Pilot-Matias, and V. Miller Hepatitis C virus drug resistance-associated substitutions: state of the art summary Hepatology 62 2015 1623 1632
23. W.P. Maddison, and D.R. Maddison MacClade-analysis of Phylogeny and Character Evolution-Version 4 2001 Sinauer Associates, Inc Sunderland, MA
24. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, R. Reindollar, Z.D. Goodman, K. Koury, M.-H. Ling, and J.K. Albrecht Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial Lancet 358 2001 958 965
25. J.A. McCauley, C.J. McIntyre, M.T. Rudd, K.T. Nguyen, J.J. Romano, J.W. Butcher, K.F. Gilbert, K.J. Bush, M.K. Holloway, J. Swestock, B.-L. Wan, S.S. Carroll, J.M. DiMuzio, D.J. Graham, S.W. Ludmerer, S.-S. Mao, M.W. Stahlhut, C.M. Fandozzi, N. Trainor, D.B. Olsen, J.P. Vacca, and N.J. Liverton Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor J. Med. Chem. 53 2010 2443 2463
26. J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, kW. M. Lee, V.K. Rustgi, Z.D. Goodman, M.-H. Ling, S. Cort, and J.K. Albrecht Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N. Engl. J. Med. 339 1998 1485 1492
27. M. Mizokami, O. Yokosuka, T. Takehara, N. Sakamoto, M. Korenaga, H. Mochizuki, K. Nakane, H. Enomoto, F. Ikeda, M. Yanase, H. Toyoda, T. Genda, T. Umemura, H. Yatsuhashi, T. Ide, N. Toda, K. Nirei, Y. Ueno, Y. Nishigaki, J. Betular, B. Gao, A. Ishizaki, M. Omote, H. Mo, K. Garrison, P.S. Pang, S.J. Knox, W.T. Symonds, J.G. McHutchison, N. Izumi, and M. Omata Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naïve and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomized, phase 3 trial Lancet Infect. Dis. 15 2015 645 653
28. M. Omata, S. Nishiguchi, Y. Ueno, H. Mochizuki, N. Izumi, F. Ikeda, H. Toyoda, O. Yokosuka, K. Nirei, T. Genda, T. Umemura, T. Takehara, N. Sakamoto, Y. Nishigaki, K. Nakane, N. Toda, T. Ide, M. Yanase, K. Hino, B. Gao, K.L. Garrison, H. Dvory-Sobol, A. Ishizaki, M. Omote, D. Brainard, S. Knox, W.T. Symonds, J.G. McHutchison, H. Yatsuhashi, and M. Mizokami Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phasee 3 trial J. Viral. Hepat. 21 2014 762 768
29. S.L. Pond, S.D. Frost, and S.V. Muse Hyphy:Hypothesis testing using phylogenics Bioinformatics 21 2005 676 679
30. A.F. Poon, F.I. Lewis, S.D. Frost, and S.L. Kosalkovsky Pond Spidermonkey: rapid detection of co-evolving sites using bayesian graphical models Bioinformatics 24 2008 1949 1950
31. M. Rodriguez-Torres, A. Stoehr, E.J. Gane, L. Serfaty, E. Lawitz, A. Zhou, M. Bourqe, S. Bhania, J. Strizki, R.J. Barnard, P.M. Hwang, M.J. DiNublile, and N. Mobashery Vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis Clin. Gastroenterol. Hepatol. 12 2014 1029 1037
32. C. Sarrazin The importance of resistance to direct antiviral drugs in HCV infection in clinical practice J. Hepatol. 64 2016 486 504
33. M. Slatkin, and W.P. Maddison A cladistic measure of gene flow inferred from the phylogenies of alleles Genetics 123 1989 603 613
34. P. Tuff, and P. Darlu Exploring a phylogenetic approach for the detection of correlated substitutions in proteins Mol. Biol. Evol. 17 2000 1753 1759
35. T. Umemura, T. Ichijo, K. Yoshizawa, E. Tanaka, and K. Kiyosawa Epidemiology of hepatocellular carcinoma in Japan J. Gastroenterol. 44 Suppl. XIX 2009 102 107